My Cart [ 0 ]
Home > Antibodies > Research-Grade Biosimilars > Ustekinumab Biosimilar, IL-12 / IL-23 Monoclonal Antibody

Ustekinumab Biosimilar, IL-12 / IL-23 Monoclonal Antibody

Interleukin 12, IL-12, IL12, IL23, IL-23, p70, IL12B, IL-12p40, Interleukin 23

Catalog No. Product Name Size List Price (US$) Quantity
C038P Ustekinumab Biosimilar, Human IL-12 / IL-23 Monoclonal Antibody 1 mg 175.00
C038P Ustekinumab Biosimilar, Human IL-12 / IL-23 Monoclonal Antibody 5 mg 600.00
C038P Ustekinumab Biosimilar, Human IL-12 / IL-23 Monoclonal Antibody 20 mg 1600.00
Description

C038P: Ustekinumab Biosimilar, IL-12 / IL-23 Monoclonal Antibody

Recombinant Humanized IgG1 Monoclonal Antibody.
Isotype: Human IgG1 lambda.
Source: The anti-human IL-12 / IL-23 monoclonal antibody ustekinumab biosimilar was produced in mammalian cells.
Specificity/Sensitivity: The in vivo grade ustekinumab biosimilar specifically binds to the human interleukin-12 (IL-12) and interleukin-23 (IL-23).
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by ustekinumab.
Form of Antibody: 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin: < 1 EU per 1 mg of the protein by the LAL method.
Purity: >95% by SDS-PAGE under reducing conditions and HPLC.

Shipping: The research grade ustekinumab biosimilar is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.

Background

What is Ustekinumab Biosimilar research grade? Ustekinumab is a human anti-IL-12 / IL-23 monoclonal antibody being developed for the treatment of a number of T-cell driven autoimmune diseases. It targets and neutralize interleukin-12 and interleukin-23, two proteins associated with inflammation, such as pro-inflammatory interleukins or tumor necrosis factor- alpha. Ustekinumab represents a novel approach to treating psoriasis, Multiple Sclerosis, Crohn’s Disease and other autoimmune and inflammatory disorders. Ustekinumab biosimilar uses the same protein sequences as the therapeutic antibody ustekinumab.

Syd Labs also provides the following anti-IL antibody biosimilar proteins:
Pascolizumab Biosimilar, research grade, anti-human IL-4 monoclonal antibody
Sarilumab Biosimilar, research grade, anti-human IL-6/IL-6R monoclonal antibody
Secukinumab Biosimilar, research grade, anti-human IL-17/IL-17a monoclonal antibody
Tocilizumab Biosimilar, research grade, anti-human IL-6/IL-6R monoclonal antibody
Briakinumab Biosimilar, research grade, anti-human IL-12/IL-23 monoclonal antibody

Related Links

See our Privacy Policy